April 16, 2025 10:38 AM EDT

Novartis terminates knee pain study; Telix reports brain tumor data

ENDPOINTS

Plus, news about Tiger Gene and Theratechnologies:

Novartis scraps knee pain drug: The Swiss drugmaker discontinued a

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

Lilly shuffles key executive positions; Mikael Dolsten takes another post-Pfizer assignment

Revolution’s KRAS drugs appear competitive in several lung cancer settings

Corvus' early-phase atopic dermatitis data prompt stock rally

AstraZeneca reports Phase 3 win for Imfinzi; Roche to build new manufacturing site in China

AI biotech Insilico Medicine goes for third attempt at Hong Kong IPO

sponsored

In one of the riskiest industries — Biotech — a surefire way to neutralize some of that risk emerges